Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure

被引：10

作者：

Suzuki, Hidekazu ^{[1
]}

Hirashima, Tomonori ^{[1
]}

Okamoto, Norio ^{[1
]}

Yamadori, Tadahiro ^{[1
]}

Tamiya, Motohiro ^{[1
]}

Morishita, Naoko ^{[1
]}

Shiroyama, Takayuki ^{[1
]}

Takeoka, Sawa ^{[1
]}

Osa, Akio ^{[1
]}

Azuma, Yuichiro ^{[1
]}

Kawase, Ichiro ^{[1
]}

机构：

[1] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Habikino, Osaka 588588, Japan

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 11卷 / 02期

关键词：

anticancer agent; non-small cell lung cancer; overall survival; progression-free survival; survival post-progression; RANDOMIZED PHASE-II; METASTATIC COLORECTAL-CANCER; VANDETANIB PLUS DOCETAXEL; 2ND-LINE TREATMENT; DOUBLE-BLIND; GEFITINIB PLUS; OPEN-LABEL; END-POINT; ERLOTINIB; PLACEBO;

D O I：

10.1111/ajco.12199

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AimThe hazard ratio of progression-free survival (PFS-HR) generally does not reflect that of overall survival (OS-HR) in advanced non-small cell lung cancer (NSCLC) patients treated with first-line therapy. Short survival post-progression (SPP) better reflects the PFS-HR and OS-HR in simulations. We aimed to evaluate whether the PFS-HR reflects the OS-HR in NSCLC clinical trials for post-first-line treatments. MethodWe reviewed clinical studies of post-first-line anticancer agents for NSCLC. We examined the sample size of the experimental arm (EA), median PFS (mPFS) or median time to progression in the EA, median overall survival (mOS) in the EA, the PFS-HR and the OS-HR. SPP was defined as the difference between mOS and mPFS. The association between mPFS and SPP, mPFS and mOS, and the PFS-HR and OS-HR was tested. We sought for the optimal point of correlation of PFS-HR and OS-HR by every 1 month of SPP. ResultsWe identified 32 trials (34 arms). mPFS and mOS were weakly correlated (correlation coefficient [r]=0.376; P=0.0286). The PFS-HR and OS-HR were also moderately correlated (r=0.415; P=0.015). The maximum r value was 0.770 (SPP<6 months; P<0.0001) when we tested the associations between the PFS-HR and OS-HR for SPP using 1-month increments. The estimated regression equation at this point was OS-HR=0.679x(PFS-HR)+0.349. ConclusionThe PFS-HR and OS-HR were strongly correlated in advanced NSCLC patients treated with post-first-line anticancer agents, with a SPP of less than 6 months.

引用

页码：121 / 128

页数：8

共 42 条

[31] Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial [J].

Ramlau, Rodryg ;

Gorbunova, Vera ;

Ciuleanu, Tudor Eliade ;

Novello, Silvia ;

Ozguroglu, Mustafa ;

Goksel, Tuncay ;

Baldotto, Clarissa ;

Bennouna, Jaafar ;

Shepherd, Frances A. ;

Le-Guennec, Solenn ;

Rey, Augustin ;

Miller, Vincent ;

Thatcher, Nicholas ;

Scagliotti, Giorgio .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) :3640-3647

[32] Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer [J].

Ready, Neal ;

Karaseva, Nina A. ;

Orlov, Sergey V. ;

Luft, Alexander V. ;

Popovych, Olexandr ;

Holmlund, Jon T. ;

Wood, Brian A. ;

Leopold, Lance .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) :781-785

[33] Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature [J].

Saad, E. D. ;

Katz, A. ;

Hoff, P. M. ;

Buyse, M. .

ANNALS OF ONCOLOGY, 2010, 21 (01) :7-12

[34] Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial [J].

Scagliotti, Giorgio V. ;

Krzakowski, Maciej ;

Szczesna, Aleksandra ;

Strausz, Janos ;

Makhson, Anatoly ;

Reck, Martin ;

Wierzbicki, Rafal F. ;

Albert, Istvan ;

Thomas, Michael ;

Abrao Miziara, Jose Elias ;

Papai, Zsolt S. ;

Karaseva, Nina ;

Thongprasert, Sumitra ;

Dalmau Portulas, Elsa ;

von Pawel, Joachim ;

Zhang, Ke ;

Selaru, Paulina ;

Tye, Lesley ;

Chao, Richard C. ;

Govindan, Ramaswamy .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2070-2078

[35] A Randomized Phase II Study of a Combination of Docetaxel and S-1 versus Docetaxel Monotherapy in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy Results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503 [J].

Segawa, Yoshihiko ;

Kiura, Katsuyuki ;

Hotta, Katsuyuki ;

Takigawa, Nagio ;

Tabata, Masahiro ;

Matsuo, Keitaro ;

Yoshioka, Hiroshige ;

Hayashi, Hidetoshi ;

Kawai, Haruyuki ;

Aoe, Keisuke ;

Maeda, Tadashi ;

Ueoka, Hiroshi ;

Tanimoto, Mitsune .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (09) :1430-1434

[36] Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer [J].

Sequist, Lecia V. ;

von Pawel, Joachim ;

Garmey, Edward G. ;

Akerley, Wallace L. ;

Brugger, Wolfram ;

Ferrari, Dora ;

Chen, Yinpu ;

Costa, Daniel B. ;

Gerber, David E. ;

Orlov, Sergey ;

Ramlau, Rodryg ;

Arthur, Susan ;

Gorbachevsky, Igor ;

Schwartz, Brian ;

Schiller, Joan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3307-3315

[37] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[38] Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non-Small-Cell Lung Cancer [J].

Smit, Egbert F. ;

Burgers, Sjaak A. ;

Biesma, Bonne ;

Smit, Hans J. M. ;

Eppinga, Pier ;

Dingemans, Anne-Marie C. ;

Joerger, Markus ;

Schellens, Jan H. ;

Vincent, Andrew ;

van Zandwijk, Nico ;

Groen, Harry J. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2038-2045

[39] Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer [J].

Spigel, David R. ;

Burris, Howard A., III ;

Greco, F. Anthony ;

Shipley, Dianna L. ;

Friedman, Elke K. ;

Waterhouse, David M. ;

Whorf, Robert C. ;

Mitchell, R. Brian ;

Daniel, Davey B. ;

Zangmeister, Jeffrey ;

Bass, J. David ;

Hainsworth, John D. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) :2582-2589

[40] Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy [J].

Tang, Patricia A. ;

Bentzen, Soren M. ;

Chen, Eric X. ;

Siu, Lillian L. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) :4562-4568

← 1 2 3 4 5 →